1. Non ‐ invasive prognostic protein biomarker signatures associated with colorectal cancer by Silvia Surinova, Lenka Radová, Meena Choi, Josef Srovnal, Hermann Brenner, Olga Vitek, Marián Hajdúch, and Ruedi Aebersold EMBO Mol Med. Volume ():e201404874 August 7, 2015 ©2015 by European Molecular Biology Organization

2. The development of biomarker signatures for the prognosis of CRC Comprehensive clinicopathological features of CRC included regional disease localization within the colorectum, histological grading, and TNM staging classification. Silvia Surinova et al. EMBO Mol Med. doi:10.15252/emmm.201404874 ©2015 by European Molecular Biology Organization

3. Biomarker signature of CRC outcome ABiomarker signature containing clinical factors and biomarker candidates predicting 5 ‐ year overall survival. Silvia Surinova et al. EMBO Mol Med. doi:10.15252/emmm.201404874 ©2015 by European Molecular Biology Organization

4. Prediction of transcriptional CRC subtypes A, BProteins from the outcome biomarker signature were used to predict (A) three colon cancer subtypes (CCSs) in the GSE33113 dataset, and (B) five cellular phenotype subtypes in the GSE33113 and GSE14333 datasets. Silvia Surinova et al. EMBO Mol Med. doi:10.15252/emmm.201404874 ©2015 by European Molecular Biology Organization

5. Biomarker signatures of additional prognostic CRC characteristics A, BSignatures for the prediction of (A) regional disease localization of colon (n = 131) and rectal (n = 71) tumors, and (B) localized (n = 150) and metastatic (n = 52) disease were also ob... Silvia Surinova et al. EMBO Mol Med. doi:10.15252/emmm.201404874 ©2015 by European Molecular Biology Organization

6. Relationship between signature proteins and their functional annotation Proteins from the biomarker signatures, including the diagnostic signature from Surinova et al (2015), were associated and interlinked by the proteins they have in common. Silvia Surinova et al. EMBO Mol Med. doi:10.15252/emmm.201404874 ©2015 by European Molecular Biology Organization